ERIS - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 2.8
| Stock Code | ERIS | Market Cap | 17,786 Cr. | Current Price | 1,286 ₹ | High / Low | 1,910 ₹ |
| Stock P/E | 59.9 | Book Value | 203 ₹ | Dividend Yield | 0.57 % | ROCE | 6.86 % |
| ROE | 3.02 % | Face Value | 1.00 ₹ | DMA 50 | 1,395 ₹ | DMA 200 | 1,492 ₹ |
| Chg in FII Hold | -0.36 % | Chg in DII Hold | 0.95 % | PAT Qtr | 17.0 Cr. | PAT Prev Qtr | 150 Cr. |
| RSI | 36.2 | MACD | -28.5 | Volume | 73,181 | Avg Vol 1Wk | 1,07,458 |
| Low price | 1,097 ₹ | High price | 1,910 ₹ | PEG Ratio | -1.38 | Debt to equity | 0.79 |
| 52w Index | 23.2 % | Qtr Profit Var | 853 % | EPS | 20.8 ₹ | Industry PE | 27.2 |
📊 ERIS currently shows weak fundamentals for long-term investment. ROE (3.02%) and ROCE (6.86%) are very low, indicating poor capital efficiency. The P/E ratio of 59.9 is more than double the industry average (27.2), suggesting significant overvaluation. The PEG ratio of -1.38 highlights misalignment between growth and valuation. Debt-to-equity is relatively high at 0.79, adding financial risk. Dividend yield is modest at 0.57%. Quarterly PAT dropped sharply (17 Cr. vs 150 Cr.), showing earnings volatility. Technical indicators (RSI 36.2, MACD -28.5) suggest weak momentum.
💡 Ideal Entry Price Zone: Current price is 1,286 ₹, below DMA 50 (1,395 ₹) and DMA 200 (1,492 ₹). An attractive entry zone would be 1,100 ₹–1,200 ₹, closer to its 52-week low (1,097 ₹). Entry should be cautious given weak fundamentals.
📈 Exit Strategy / Holding Period: For existing holders, short-to-medium-term holding (1–2 years) is advisable only if earnings stabilize. Exit strategy should be considered if price rebounds toward 1,800 ₹–1,910 ₹ (recent highs) without improvement in ROE/ROCE. Long-term holding is not recommended unless profitability metrics improve significantly.
✅ Positive
- EPS of 20.8 ₹ supports valuation strength.
- DII holdings increased (+0.95%), reflecting domestic institutional support.
- 52-week performance shows 23.2% gain.
⚠️ Limitation
- P/E ratio (59.9) is much higher than industry average (27.2).
- ROE (3.02%) and ROCE (6.86%) are weak.
- PEG ratio (-1.38) indicates poor growth valuation alignment.
- Debt-to-equity ratio (0.79) is relatively high.
📉 Company Negative News
- Quarterly PAT dropped sharply (17 Cr. vs 150 Cr.).
- FII holdings decreased (-0.36%), showing reduced foreign confidence.
- Technical indicators (RSI 36.2, MACD -28.5) suggest weak momentum.
📈 Company Positive News
- Quarterly profit variation (+853%) indicates recovery from a low base.
- DII holdings increased (+0.95%), showing domestic support.
- EPS of 20.8 ₹ highlights profitability despite weak margins.
🏭 Industry
- Industry P/E is 27.2, much lower than company’s 59.9, suggesting ERIS trades at a premium.
- Pharmaceutical sector outlook remains positive with steady demand growth.
🔎 Conclusion
ERIS is currently overvalued with weak profitability metrics and high debt levels. Current price near 1,286 ₹ offers limited long-term value. Entry is only advisable closer to 1,100 ₹–1,200 ₹ if fundamentals improve. Existing holders should consider exiting near 1,800 ₹–1,910 ₹ unless ROE and ROCE show significant recovery. Overall, the stock is a risky candidate for long-term investment and better suited for cautious medium-term strategies.